Novelos Therapeutics, Inc., a biotechnology company, offers oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The company’s primary product NOV-002, a small-molecule derivative of a natural metabolite, is developed in combination with chemotherapy for the treatment of lung and ovarian cancer. NOV-002 is also designed to act as a cytoprotectant and an immunomodulator, as well as developed for the treatment of ovarian cancer and acute radiation injury. The company’s another product, NOV-205 is a small-molecule formulation of oxidized glutathione and inosine for the treatment of chronic hepatitis C. NOV-205 is designed to act as a hepatoprotective agent with immunomodulating and antiviral activity. Novelos Therapeutics is based in Newton, Massachusetts.